CoChat

Cell-free microRNAs in Parkinson’s disease: potential biomarkers that provide new insights into disease pathogenesis

Doxakis, Epaminondas · 2020 · Ageing Research Reviews
Cited by 22

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

MicroRNAs (miRNAs) are master post-transcriptional regulators of gene expression and their specific footprints reflect disease conditions. Over the last few years, several primary reports have described the deregulation of cell-free miRNAs in Parkinson's disease (PD), however, results have been rather inconsistent due to preanalytical and analytical challenges. This study integrated the data across twenty-four reports to identify steadily deregulated miRNAs that may assist in the path towards biomarker development and molecular characterization of the underlying pathology. Stringent KEGG pathway analysis of the miRNA targets revealed FoxO, Prolactin, TNF, and ErbB signaling pathways as the most significantly enriched categories while Gene Ontology analysis revealed that the protein targets are mostly associated with transcription. Chromosomal location of the consistently deregulated miRNAs revealed that over a third of them were clustered at the same location at Chr14q32 suggesting that they are co-regulated by specific transcription factors. This genomic region is inherently unstable due to expanded TGG repeats and responsible for human abnormalities. Stringent analysis of transcription factor sites surrounding the deregulated miRNAs revealed that CREB1, CEBPB and MAZ sites existed in approximately half of the miRNAs, including all of the miRNAs located at Chr14q32. Additional studies are now needed to determine the biomarker potential of the consistently deregulated miRNAs…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.arr.2020.101023

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 116

  1. Abbas, 2018, Epidemiology of parkinson’s disease-east versus west, Mov. Disord. Clin. Pract., 5, 14, 10.1002/mdc3.12568 · DOI · Paper page
  2. Agarwal, 2015, Predicting effective microRNA target sites in mammalian mRNAs, eLife, 4
  3. Aloe, 1997, TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior, Neurosci. Lett., 238, 65, 10.1016/S0304-3940(97)00850-1 · DOI
  4. Andersen, 2004, Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets, Cancer Res., 64, 5245, 10.1158/0008-5472.CAN-04-0496 · DOI · Paper page
  5. Arroyo, 2011, Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma, Proc. Natl. Acad. Sci. U.S.A., 108, 5003, 10.1073/pnas.1019055108 · DOI · Paper page
  6. Bai, 2017, Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease, Sci. Rep., 7, 5411, 10.1038/s41598-017-03887-3 · DOI · Paper page
  7. Bail, 2010, Differential regulation of microRNA stability, RNA, 16, 1032, 10.1261/rna.1851510 · DOI · Paper page
  8. Balcells, 2011, Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers, BMC Biotechnol., 11, 70, 10.1186/1472-6750-11-70 · DOI · Paper page
  9. Bellomo, 1991, Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s disease, J. Neurol., 238, 19, 10.1007/BF00319704 · DOI
  10. Bena, 2010, A recurrent 14q32.2 microdeletion mediated by expanded TGG repeats, Hum. Mol. Genet., 19, 1967, 10.1093/hmg/ddq075 · DOI · Paper page
  11. Bhidayasiri, 2017, Clinical assessments in parkinson’s disease: scales and monitoring, Int. Rev. Neurobiol., 132, 129, 10.1016/bs.irn.2017.01.001 · DOI
  12. Bielefeld, 2019, Co-administration of Anti microRNA-124 and -137 Oligonucleotides Prevents Hippocampal Neural Stem Cell Loss Upon Non-convulsive Seizures, Front. Mol. Neurosci., 12, 31, 10.3389/fnmol.2019.00031 · DOI
  13. Blondal, 2013, Assessing sample and miRNA profile quality in serum and plasma or other biofluids, Methods, 59, S1, 10.1016/j.ymeth.2012.09.015 · DOI · Paper page
  14. Boka, 1994, Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease, Neurosci. Lett., 172, 151, 10.1016/0304-3940(94)90684-X · DOI · Paper page
  15. Botta-Orfila, 2014, Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease, J. Neurosci. Res., 92, 1071, 10.1002/jnr.23377 · DOI · Paper page
  16. Buiting, 2008, Clinical features of maternal uniparental disomy 14 in patients with an epimutation and a deletion of the imprinted DLK1/GTL2 gene cluster, Hum. Mutat., 29, 1141, 10.1002/humu.20771 · DOI · Paper page
  17. Burgos, 2013, Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing, Rna, 19, 712, 10.1261/rna.036863.112 · DOI · Paper page
  18. Cao, 2018, Long noncoding RNA SNHG1 promotes neuroinflammation in parkinson’s disease via regulating miR-7/NLRP3 pathway, Neuroscience, 388, 118, 10.1016/j.neuroscience.2018.07.019 · DOI · Paper page
  19. Cardo, 2013, Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls, J. Neurol., 260, 1420, 10.1007/s00415-013-6900-8 · DOI · Paper page
  20. Carvey, 2005, Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat, J. Neural Transm., 112, 601, 10.1007/s00702-004-0222-z · DOI
  21. Chen, 2018, Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative disease models, EMBO Rep., 19
  22. Cho, 2013, MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein, Hum. Mol. Genet., 22, 608, 10.1093/hmg/dds470 · DOI · Paper page
  23. Choi, 2014, MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA, J. Neurosci., 34, 12725, 10.1523/JNEUROSCI.0985-14.2014 · DOI · Paper page
  24. Choi, 2018, MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy, Neurosci. Lett., 678, 118, 10.1016/j.neulet.2018.05.009 · DOI · Paper page
  25. Das, 1996, Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells, Oncogene, 13, 1139
  26. Ding, 2016, Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease, Parkinsonism Relat. Disord., 22, 68, 10.1016/j.parkreldis.2015.11.014 · DOI · Paper page
  27. Doan, 2016, FoxO1 in dopaminergic neurons regulates energy homeostasis and targets tyrosine hydroxylase, Nat. Commun., 7, 12733, 10.1038/ncomms12733 · DOI · Paper page
  28. Dong, 2016, A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease, Biomarkers, 21, 129, 10.3109/1354750X.2015.1118544 · DOI · Paper page
  29. Dong, 2018, The neuroprotective role of MiR-124-3p in a 6-Hydroxydopamine-Induced cell model of parkinson’s disease via the regulation of ANAX5, J. Cell. Biochem., 119, 269, 10.1002/jcb.26170 · DOI · Paper page
  30. Dos Santos, 2018, miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease, Oncotarget, 9, 17455, 10.18632/oncotarget.24736 · DOI · Paper page
  31. Doxakis, 2010, Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153, J. Biol. Chem., 285, 12726, 10.1074/jbc.M109.086827 · DOI · Paper page
  32. Doxakis, 2013, Principles of miRNA-Target regulation in metazoan models, Int. J. Mol. Sci., 14, 16280, 10.3390/ijms140816280 · DOI
  33. Dumitriu, 2016, Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease, BMC Med. Genomics, 9, 5, 10.1186/s12920-016-0164-y · DOI · Paper page
  34. Eisler, 1981, Prolactin secretion in Parkinson disease, Neurology, 31, 1356, 10.1212/WNL.31.10.1356 · doi:10.1212/wnl.31.10.1356
  35. El-Khoury, 2016, Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material, Sci. Rep., 6, 19529, 10.1038/srep19529 · DOI · Paper page
  36. Fehlmann, 2016, Distribution of microRNA biomarker candidates in solid tissues and body fluids, RNA Biol., 13, 1084, 10.1080/15476286.2016.1234658 · DOI · Paper page
  37. Fragkouli, 2014, miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway, Front. Cell. Neurosci., 8, 182, 10.3389/fncel.2014.00182 · DOI · Paper page
  38. Gehrke, 2010, Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression, Nature, 466, 637, 10.1038/nature09191 · DOI · Paper page
  39. Geng, 2017, miR-124-3p attenuates MPP(+)-induced neuronal injury by targeting STAT3 in SH-SY5Y cells, Exp. Biol. Med., 242, 1757, 10.1177/1535370217734492 · DOI · Paper page
  40. Gong, 2016, miR-124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK/mTOR pathway in Parkinson’s disease, Am. J. Transl. Res., 8, 2127
  41. Guo, 2014, Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues, Sci. Rep., 4, 5150, 10.1038/srep05150 · DOI · Paper page
  42. Hansen, 2016, Targeted deletion of miR-132/-212 impairs memory and alters the hippocampal transcriptome, Learn. Mem., 23, 61, 10.1101/lm.039578.115 · DOI · Paper page
  43. He, 2007, The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation, Neuron, 55, 217, 10.1016/j.neuron.2007.06.029 · DOI · Paper page
  44. Hermanson, 2003, Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells, Exp. Cell Res., 288, 324, 10.1016/S0014-4827(03)00216-7 · DOI · Paper page
  45. Hernandez-Rapp, 2015, Memory formation and retention are affected in adult miR-132/212 knockout mice, Behav. Brain Res., 287, 15, 10.1016/j.bbr.2015.03.032 · DOI · Paper page
  46. Hu, 2017, MiR-218 induces neuronal differentiation of ASCs in a temporally sequential manner with fibroblast growth factor by regulation of the wnt signaling pathway, Sci. Rep., 7, 39427, 10.1038/srep39427 · DOI
  47. Huang da, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat. Protoc., 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  48. Hunter, 2008, Detection of microRNA expression in human peripheral blood microvesicles, PLoS One, 3, e3694, 10.1371/journal.pone.0003694 · DOI · Paper page
  49. Iwakura, 2005, Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson’s disease and its model: neurotrophic implication in nigrostriatal neurons, J. Neurochem., 93, 974, 10.1111/j.1471-4159.2005.03073.x · DOI · Paper page
  50. Jiang, 2005, Age-dependent dopaminergic dysfunction in Nurr1 knockout mice, Exp. Neurol., 191, 154, 10.1016/j.expneurol.2004.08.035 · DOI
  51. Jin, 2018, Elevated microRNA-520d-5p in the serum of patients with Parkinson’s disease, possibly through regulation of cereloplasmin expression, Neurosci. Lett., 687, 88, 10.1016/j.neulet.2018.09.034 · DOI
  52. John, 2004, Human MicroRNA targets, PLoS Biol., 2, e363, 10.1371/journal.pbio.0020363 · DOI · Paper page
  53. Kanao, 2010, Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila, Hum. Mol. Genet., 19, 3747, 10.1093/hmg/ddq289 · DOI · Paper page
  54. Kelly, 1997, Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice, Neuron, 19, 103, 10.1016/S0896-6273(00)80351-7 · DOI · Paper page
  55. Khoo, 2012, Plasma-based circulating MicroRNA biomarkers for Parkinson’s disease, J. Parkinsons Dis., 2, 321, 10.3233/JPD-012144 · DOI · Paper page
  56. Kim, 2003, Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner, J. Neurochem., 85, 622, 10.1046/j.1471-4159.2003.01671.x · DOI · Paper page
  57. Klein, 2007, Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder, Neurology, 69, 2093, 10.1212/01.wnl.0000271880.27321.a7 · DOI · Paper page
  58. Knauss, 2018, Long noncoding RNA Sox2ot and transcription factor YY1 co-regulate the differentiation of cortical neural progenitors by repressing Sox2, Cell Death Dis., 9, 799, 10.1038/s41419-018-0840-2 · DOI
  59. Koh, 2012, Silent information regulator 2 (Sir2) and Forkhead box O (FOXO) complement mitochondrial dysfunction and dopaminergic neuron loss in Drosophila PTEN-induced kinase 1 (PINK1) null mutant, J. Biol. Chem., 287, 12750, 10.1074/jbc.M111.337907 · DOI · Paper page
  60. Kruger, 2000, Genetic analysis of immunomodulating factors in sporadic Parkinson’s disease, J. Neural Transm., 107, 553, 10.1007/s007020070078 · DOI · Paper page
  61. Le, 1999, Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury, J. Neurochem., 73, 2218, 10.1046/j.1471-4159.1999.02218.x · DOI · Paper page
  62. Li, 2016, SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1alpha-mediated mitochondrial biogenesis, Oncotarget, 7, 29255, 10.18632/oncotarget.8711 · DOI
  63. Li, 2017, Plasma levels of miR-137 and miR-124 are associated with Parkinson’s disease but not with Parkinson’s disease with depression, Neurol. Sci., 38, 761, 10.1007/s10072-017-2841-9 · DOI · Paper page
  64. Lim, 2005, Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature, 433, 769, 10.1038/nature03315 · DOI · Paper page
  65. Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI · Paper page
  66. Ma, 2016, Serum miR-221 serves as a biomarker for Parkinson’s disease, Cell Biochem. Funct., 34, 511, 10.1002/cbf.3224 · DOI · Paper page
  67. McAlexander, 2013, Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid, Front. Genet., 4, 83, 10.3389/fgene.2013.00083 · DOI · Paper page
  68. McGeer, 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains, Neurology, 38, 1285, 10.1212/WNL.38.8.1285 · DOI · Paper page
  69. McGuire, 2001, Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons, Exp. Neurol., 169, 219, 10.1006/exnr.2001.7688 · DOI · Paper page
  70. McMillan, 2017, Loss of MicroRNA-7 regulation leads to alpha-synuclein accumulation and dopaminergic neuronal loss in vivo, Mol. Ther., 25, 2404, 10.1016/j.ymthe.2017.08.017 · DOI · Paper page
  71. Miller, 2015, Biomarkers of Parkinson’s disease: present and future, Metab. Clin. Exp., 64, S40, 10.1016/j.metabol.2014.10.030 · DOI · Paper page
  72. Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. U.S.A., 105, 10513, 10.1073/pnas.0804549105 · DOI · Paper page
  73. Mitchell, 2013, Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion, Acta Neuropathol., 125, 273, 10.1007/s00401-012-1043-z · DOI · Paper page
  74. Mogi, 2000, Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain, J. Neural Transm., 107, 335, 10.1007/s007020050028 · DOI · Paper page
  75. Mooney, 2015, High throughput qPCR expression profiling of circulating MicroRNAs reveals minimal sex- and sample timing-related variation in plasma of healthy volunteers, PLoS One, 10, 10.1371/journal.pone.0145316 · DOI · Paper page
  76. Mouradian, 2012, MicroRNAs in Parkinson’s disease, Neurobiol. Dis., 46, 279, 10.1016/j.nbd.2011.12.046 · DOI · Paper page
  77. Nishimura, 2001, Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease, Neurosci. Lett., 311, 1, 10.1016/S0304-3940(01)02111-5 · DOI
  78. Nitkowska, 2015, Prolactin and sex hormones levels in males with Parkinson’s disease, Acta Neurol. Scand., 131, 411, 10.1111/ane.12334 · DOI · Paper page
  79. Olejniczak, 2013, Long-lived microRNA-Argonaute complexes in quiescent cells can be activated to regulate mitogenic responses, Proc. Natl. Acad. Sci. U.S.A., 110, 157, 10.1073/pnas.1219958110 · DOI · Paper page
  80. Paschou, 2012, Neurofibromin 1 is a miRNA target in neurons, PLoS One, 7, 10.1371/journal.pone.0046773 · DOI · Paper page
  81. Paschou, 2012, miRNA regulons associated with synaptic function, PLoS One, 7, 10.1371/journal.pone.0046189 · DOI · Paper page
  82. Patti, 2003, Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1, Proc. Natl. Acad. Sci. U.S.A., 100, 8466, 10.1073/pnas.1032913100 · DOI · Paper page
  83. Pezet, 1997, The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor, Mol. Cell. Endocrinol., 129, 199, 10.1016/S0303-7207(97)00063-4 · DOI
  84. Pfaffl, 2004, Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--excel-based tool using pair-wise correlations, Biotechnol. Lett., 26, 509, 10.1023/B:BILE.0000019559.84305.47 · DOI · Paper page
  85. Postuma, 2015, MDS clinical diagnostic criteria for Parkinson’s disease, Mov. Disord., 30, 1591, 10.1002/mds.26424 · DOI · Paper page
  86. Ramon-Nunez, 2017, Comparison of protocols and RNA carriers for plasma miRNA isolation. Unraveling RNA carrier influence on miRNA isolation, PLoS One, 12, 10.1371/journal.pone.0187005 · DOI
  87. Ravanidis, 2019, Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson’s disease, Mov. Disord.
  88. Sakurada, 1999, Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain, Development, 126, 4017, 10.1242/dev.126.18.4017 · DOI · Paper page
  89. Schaefer, 2008, Pituitary function and the somatotrophic system in patients with idiopathic Parkinson’s disease under chronic dopaminergic therapy, J. Neuroendocrinol., 20, 104, 10.1111/j.1365-2826.2007.01622.x · doi:10.1111/j.1365-2826.2007.01622.x
  90. Scherzer, 2008, GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein, Proc. Natl. Acad. Sci. U.S.A., 105, 10907, 10.1073/pnas.0802437105 · DOI · Paper page
  91. Schimmel, 1999, 4.5 kb of the rat tyrosine hydroxylase 5’ flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors, Brain Res. Mol. Brain Res., 74, 1, 10.1016/S0169-328X(99)00234-X · DOI
  92. Schouten, 2015, MicroRNA-124 and -137 cooperativity controls caspase-3 activity through BCL2L13 in hippocampal neural stem cells, Sci. Rep., 5, 12448, 10.1038/srep12448 · DOI · Paper page
  93. Scott, 2012, MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex, Eur. J. Neurosci., 36, 2941, 10.1111/j.1460-9568.2012.08220.x · DOI · Paper page
  94. Shen, 2014, Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating Peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha), Cell Stress Chaperones, 19, 541, 10.1007/s12192-013-0480-5 · DOI
  95. Skirzewski, 2018, ErbB4 signaling in dopaminergic axonal projections increases extracellular dopamine levels and regulates spatial/working memory behaviors, Mol. Psychiatry, 23, 2227, 10.1038/mp.2017.132 · DOI · Paper page
  96. St-Pierre, 2006, Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators, Cell, 127, 397, 10.1016/j.cell.2006.09.024 · DOI · Paper page
  97. Tan, 2013, MicroRNA-128 governs neuronal excitability and motor behavior in mice, Science, 342, 1254, 10.1126/science.1244193 · DOI · Paper page
  98. Tas, 2018, Parallel roles of transcription factors dFOXO and FER2 in the development and maintenance of dopaminergic neurons, PLoS Genet., 14, 10.1371/journal.pgen.1007271 · DOI
  99. Tysnes, 2017, Epidemiology of Parkinson’s disease, J. Neural Transm., 124, 901, 10.1007/s00702-017-1686-y · DOI · Paper page
  100. Valbuena, 2019, The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing, Sci. Rep., 9, 15787, 10.1038/s41598-019-51948-6 · DOI · Paper page
  101. Vallelunga, 2014, Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and Multiple System Atrophy, Front. Cell. Neurosci., 8, 156, 10.3389/fncel.2014.00156 · DOI · Paper page
  102. Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol., 3, 10.1186/gb-2002-3-7-research0034 · DOI · Paper page
  103. Wang, 2012, Comparing the MicroRNA spectrum between serum and plasma, PLoS One, 7
  104. Wang, 2019, MicroRNA-124 enhances dopamine receptor expression and neuronal proliferation in mouse models of parkinson’s disease via the hedgehog signaling pathway by targeting EDN2, Neuroimmunomodulation, 1
  105. Weishaupt, 2019, Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes, Bioinformatics, 35, 3357, 10.1093/bioinformatics/btz066 · DOI
  106. Wolfe, 2013, Visualizing genomic information across chromosomes with PhenoGram, BioData Min., 6, 18, 10.1186/1756-0381-6-18 · DOI · Paper page
  107. Wu, 2007, Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson’s disease, Am. J. Med. Genet. B Neuropsychiatr. Genet., 144B, 300, 10.1002/ajmg.b.30435 · DOI · Paper page
  108. Xu, 2011, JNK regulates FoxO-dependent autophagy in neurons, Genes Dev., 25, 310, 10.1101/gad.1984311 · DOI · Paper page
  109. Yamauchi, 1998, Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase, J. Biol. Chem., 273, 15719, 10.1074/jbc.273.25.15719 · DOI · Paper page
  110. Yang, 2012, miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression, J. Cell. Sci., 125, 1673
  111. Yang, 2019, Altered expression levels of MicroRNA-132 and Nurr1 in peripheral blood of parkinson’s disease: potential disease biomarkers, ACS Chem. Neurosci., 10, 2243, 10.1021/acschemneuro.8b00460 · DOI · Paper page
  112. Yao, 2018, MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease, J. Neuroinflammation, 15, 13, 10.1186/s12974-018-1053-4 · DOI · Paper page
  113. Yeri, 2018, Evaluation of commercially available small RNASeq library preparation kits using low input RNA, BMC Genomics, 19, 331, 10.1186/s12864-018-4726-6 · DOI · Paper page
  114. Zada, 2014, A rare, recurrent, de novo 14q32.2q32.31 microdeletion of 1.1 mb in a 20-Year-Old female patient with a maternal UPD(14)-Like phenotype and intellectual disability, Case reports in genetics, 2014, 10.1155/2014/530134 · DOI · Paper page
  115. Zetterstrom, 1997, Dopamine neuron agenesis in Nurr1-deficient mice, Science, 276, 248, 10.1126/science.276.5310.248 · DOI · Paper page
  116. Zhang, 2017, Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for parkinson’s disease, Front. Cell. Neurosci., 11, 170, 10.3389/fncel.2017.00170 · DOI · Paper page

Cited by

See all 22

Metadata

Authors
Doxakis, E.
Venue
Ageing Research Reviews
Publisher
Elsevier BV
Published
2020-03
Volume
58
Pages
101023
ISSN
1568-1637
Cited by
22
References
34
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell-free microRNAs in Parkinson’s disease: potential biomarkers that provide new insights into disease pathogenesis. https://app.cochat.ai/papers/10.1016/j.arr.2020.101023
The paper
Doxakis, E. (2020). Cell-free microRNAs in Parkinson’s disease: potential biomarkers that provide new insights into disease pathogenesis. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2020.101023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.